Biopharmaceutical firm Access Pharmaceuticals (ACCP) has secured European patent (EP1997478) for MuGard, which offers the oral muscosa with a thin protective hydrogel layer.
Oral muscosa has been confirmed in many clinical studies to benefit patients in terms of reducing pain, discomfort and reduction in objective mucositis scores.
The patent secured from the European Patent Office protects a range of liquid formulations for the prevention and treatment of mucosal diseases and disorders.
Access Pharmaceuticals senior vice president of research and development David Nowotnik said the second patent for MuGard in the EU provides the company with additional protection of the mucoadhesive liquid technology that forms the basis of MuGard.
"The new patent also provides us with additional protection of formulations which could form the basis of potential MuGard line extension products," Nowotnik said.
MuGard Mucoadhesive Oral Wound Rinse, an oral mucoadhesive, is designed to manage oral mucositis by forming a protective hydrogel coating over the oral mucosa to guard the membranes of the mouth and tongue.
Access president and CEO Jeffrey Davis said, "Our new patent in Europe expands and strengthens our MuGard patent portfolio, and we anticipate that current and future formulations of MuGard might also benefit patients with various other ulcerative conditions with the oral cavity such as oral lichen planus."
